Prognostic impact of EGFR mutations in T1-4N0M0 lung adenocarcinoma: analyses focus on imaging and pathological features.

Autor:	Chen JY; Department of Oncology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Zhu Y; Department of Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Liu BC; Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Ma HY; Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Li LJ; Department of Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Chen MC; Department of Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Zhou SC; Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Li XM; Department of Radiology, Hui Ya Hospital of the First Affiliated Hospital, Sun Yat-sen University, Huizhou, China., Long JT; Department of Oncology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Li Q; Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Jazyk:	angličtina
Zdroj:	Journal of thoracic disease [J Thorac Dis] 2024 Nov 30; Vol. 16 (11), pp. 7244-7256. Date of Electronic Publication: 2024 Nov 29.
DOI:	10.21037/jtd-24-724
Abstrakt:	Background: With the development of tyrosine kinase inhibitor (TKI) treatment, the prognosis of advanced lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor ( EGFR ) mutations has been continuously improving. This study aims to propose the utilization of pathological characteristics and imaging features to evaluate the impact of EGFR gene mutations on the prognosis of T1-4N0M0 LUAD. Methods: Among the cases diagnosed with LUAD between April 2015 and April 2016, 438 patients with T1-4N0M0 LUAD were included, and the clinical characteristics were collected. EGFR mutations were analyzed in these patients who underwent lobectomy with different radiological and pathological types for the relation to patient prognosis. Results: Patients with EGFR mutation had longer recurrence-free survival (RFS) in part-solid nodules cohort (P=0.03), which was in contrast to purely solid nodules (P=0.06). Positive EGFR mutations significantly prolonged RFS in nodules consolidation-to-tumor ratio (CTR) values of 0-0.5. In the International Association for the Study of Lung Cancer (IASLC) grade I patients with EGFR mutations, there was a trend towards longer RFS but with no effect on overall survival (OS) (P=0.08; P=0.71); in IASLC grade II patients with EGFR mutations, there was a tendency of longer OS (P=0.06); in IASLC grade III patients with EGFR mutations, both RFS and OS were significantly shorter (P=0.02; P=0.005). EGFR mutation state was not an independent risk factors for both RFS and OS. Conclusions: EGFR mutations are associated with a favorable prognosis in nodules with lower IASLC grading or more ground glass opacity (GGO) components. The results were reversed in patients with higher IASLC grading or no GGO component. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-724/coif). The authors have no conflicts of interest to declare. (2024 AME Publishing Company. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu